Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year. Biopharmaceutical initial ...

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

EU member states are set to launch the EU Health Data Space Regulation for harmonised data transfer on 26 March.

Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease ...

Ensuring the highest standards in pharmaceutical logistics is crucial for patient safety and treatment efficacy.

The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...